BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22246507)

  • 1. ABCG2 null alleles define the Jr(a-) blood group phenotype.
    Zelinski T; Coghlan G; Liu XQ; Reid ME
    Nat Genet; 2012 Jan; 44(2):131-2. PubMed ID: 22246507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the JR blood group system.
    Castilho L; Reid ME
    Immunohematology; 2013; 29(2):63-8. PubMed ID: 24094238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new ABCG2 null allele with a 27-kb deletion including the promoter region causing the Jr(a-) phenotype.
    Ogasawara K; Osabe T; Suzuki Y; Tsuneyama H; Isa K; Kawai M; Obara K; Ogiyama Y; Ito S; Uchikawa M; Satake M; Tadokoro K
    Transfusion; 2015 Jun; 55(6 Pt 2):1467-71. PubMed ID: 25522810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The JR blood group system (ISBT 032): molecular characterization of three new null alleles.
    Hue-Roye K; Lomas-Francis C; Coghlan G; Zelinski T; Reid ME
    Transfusion; 2013 Jul; 53(7):1575-9. PubMed ID: 23066723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of immunized Jr(a-) or Lan- patients and validation of a high-throughput genotyping assay to screen blood donors for Jr(a-) and Lan- phenotypes.
    Haer-Wigman L; Ait Soussan A; Ligthart P; de Haas M; van der Schoot CE
    Transfusion; 2014 Jul; 54(7):1836-46. PubMed ID: 24456066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
    Saison C; Helias V; Ballif BA; Peyrard T; Puy H; Miyazaki T; Perrot S; Vayssier-Taussat M; Waldner M; Le Pennec PY; Cartron JP; Arnaud L
    Nat Genet; 2012 Jan; 44(2):174-7. PubMed ID: 22246505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JR blood group system: identification of alleles that alter expression.
    Hue-Roye K; Zelinski T; Cobaugh A; Lomas-Francis C; Miyazaki T; Tani Y; Westhoff CM; Reid ME
    Transfusion; 2013 Nov; 53(11):2710-4. PubMed ID: 23438071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the Jr(a-) phenotype in the Japanese population.
    Tanaka M; Kamada I; Takahashi J; Kimura K; Matsukura H; Tani Y
    Transfusion; 2014 Feb; 54(2):412-7. PubMed ID: 23713577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the JR blood group system.
    Castilho L
    Immunohematology; 2019 Jun; 35(2):43-44. PubMed ID: 31246485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel ABCG2 variant causing Jr(a-) phenotype.
    Kwon SS; Yun YE; Kim NH; Suh EJ; Kim SK; Kim S
    Transfusion; 2024 Apr; 64(4):E9-E10. PubMed ID: 38361420
    [No Abstract]   [Full Text] [Related]  

  • 11. Genotyping of the ABCG2 gene using Matrix-Associated Laser Desorption/Ionisation, Time-of-Flight Mass Spectrometry.
    Tanaka M; Kamada I; Takahashi J; Kimura T; Tani Y
    Transfus Med; 2018 Jun; 28(3):255-260. PubMed ID: 28940904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two novel ABCG2 alleles resulting in a Jr(a-) phenotype.
    Berardi P; Cote J; Vege S; Aeschlimann J; Cserti-Gazdewich C; Westhoff CM
    Transfusion; 2017 Nov; 57(11):2811-2812. PubMed ID: 28836283
    [No Abstract]   [Full Text] [Related]  

  • 13. Deletion of Exons 3 through 5 of ABCG2 causes the Jr(a-) phenotype in a West African woman.
    Saison C; Cartron JP; Arnaud L
    Transfusion; 2015 Nov; 55(11):2766-7. PubMed ID: 26173500
    [No Abstract]   [Full Text] [Related]  

  • 14. A new genetic background for the Jr(a-) blood group phenotype caused by the ABCG2*439T allele encoding a p.Arg147Trp change.
    Wieckhusen C; Rink G; Scharberg EA; Rothenberger S; Stürtzel A; Richter E; Bugert P
    Transfusion; 2017 Dec; 57(12):3063-3064. PubMed ID: 29106709
    [No Abstract]   [Full Text] [Related]  

  • 15. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
    Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
    Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
    Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T
    Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population.
    Bosch TM; Kjellberg LM; Bouwers A; Koeleman BP; Schellens JH; Beijnen JH; Smits PH; Meijerman I
    Am J Pharmacogenomics; 2005; 5(2):123-31. PubMed ID: 15813675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population.
    Bäckström G; Taipalensuu J; Melhus H; Brändström H; Svensson AC; Artursson P; Kindmark A
    Eur J Pharm Sci; 2003 Apr; 18(5):359-64. PubMed ID: 12694888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
    Woodward OM; Köttgen A; Coresh J; Boerwinkle E; Guggino WB; Köttgen M
    Proc Natl Acad Sci U S A; 2009 Jun; 106(25):10338-42. PubMed ID: 19506252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.